RIO DE JANEIRO, BRAZIL - Preclinical testing of candidates for the novel coronavirus (Sars-CoV-2) vaccine in Italy proved positive. In an interview with ANSA news agency on Friday, April 10th, Luigi Aurisicchio, CEO of the Roman company Takis Biotech, which is conducting studies with five vaccines, said there was "strong antibody production" with a single dose.
"The first results in the pre-clinical models have shown strong immunogenicity of vaccine candidates," said Aurisicchio, adding that two of them appear more promising. Final results are expected by mid-May, and testing in humans could begin in September.
All five vaccines . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here